Zepbound vs Ozempic: Dual vs Single Incretin Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Inside the PlexusDx Education Hub you'll find evidence-based coverage of GLP-1 therapies, weight-management protocols, and the genetics behind each metabolic decision. Browse all Peptides & GLP-1 education

This comparison is editorially independent. PlexusDx has no commercial relationship with Eli Lilly or Novo Nordisk.

Unlike two brands of the same drug, Zepbound and Ozempic are genuinely different molecules that take different routes to a similar destination. One is a dual incretin agonist, the other a single-target GLP-1 agonist. This article, current as of April 2026, compares their receptor strategies, approved uses, evidence, and the inherited variables that apply to either.

Two different molecules, two receptor strategies

Zepbound is tirzepatide, a GIP and GLP-1 dual receptor agonist from Eli Lilly. Ozempic is semaglutide, a selective GLP-1 receptor agonist from Novo Nordisk. Both slow gastric emptying, blunt post-meal glucose excursions, and boost satiety signaling through the GLP-1 receptor — but only tirzepatide also activates the GIP receptor. That added arm is the defining molecular difference between the two.

Approved uses: obesity versus diabetes

Zepbound is approved for chronic weight management (2023) in adults with BMI ≥ 30, or ≥ 27 with a weight-related condition, with a 2024 expansion into moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic is approved for type 2 diabetes (2017) and is widely studied for weight outcomes as the same active ingredient. These indication scopes govern how each is prescribed and whether insurance covers the cost.

SURMOUNT against SUSTAIN

Zepbound's record comes from the SURMOUNT program (SURMOUNT-OSA for sleep apnea), while Ozempic's comes from the SUSTAIN program on cardiovascular and glycemic outcomes. Indirect comparisons exist across programs, and SURPASS evaluated tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes. Because populations and endpoints differ, the cleanest interpretation stays per-trial rather than crowning an overall winner.

Tolerability and class warnings

Both molecules carry the GLP-1 class boxed warning tied to thyroid C-cell tumor risk seen in rodent studies. Gastrointestinal effects dominate the common side-effect list — nausea, vomiting, diarrhea, and constipation — and tend to peak during dose escalation. Rarer but serious events across the class include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

The list-price gap and coverage

Zepbound's U.S. list price runs approximately $1,059 per month (Eli Lilly published pricing), while Ozempic's runs approximately $968 to $1,029 per month (Novo Nordisk published pricing), both as of April 2026. Out-of-pocket cost turns on insurance coverage, savings-card eligibility, the indication written on the prescription, and whether a compounded alternative is available through a licensed compounding pathway.

Genes beneath both compounds

Regardless of which molecule a clinician chooses, the upstream architecture overlaps. Variants in GIPR (the GIP receptor, relevant to tirzepatide's second arm), GLP1R, FTO, and MC4R shape baseline appetite regulation, satiety signaling, and energy expenditure. These are pathway-level markers — they do not predict response to semaglutide or tirzepatide, but they describe the terrain each has to work within.

PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide protocol. The upstream context is the differentiator: before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including GIPR, GLP1R, FTO, and MC4R variants that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. That is the test before you invest approach.

Related reading on PlexusDx: Ozempic for Sale, Ozempic for Prediabetes, Is Semaglutide the Same As Ozempic, Ozempic Online.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols and covers the mechanism, evidence, and genetic context that inform any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats inside the PlexusDx Weight Management Protocols, or start upstream with the Precision Peptide Genetic Test to understand your GLP-1 pathway biology first.

Frequently Asked Questions

What is the core mechanical difference between Zepbound and Ozempic?

Zepbound (tirzepatide) engages both the GIP and GLP-1 receptors, while Ozempic (semaglutide) engages only the GLP-1 receptor. Both slow gastric emptying and raise satiety signaling, but only tirzepatide adds the GIP arm — the single feature that most distinguishes the two molecules pharmacologically.

Is one approved for weight loss and the other for diabetes?

Broadly, yes. Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea, while Ozempic is approved for type 2 diabetes. The indication a prescription is written under drives both how each is prescribed and how insurers decide whether to cover it.

Which one costs more?

By U.S. list price as of April 2026, Zepbound runs about $1,059 per month and Ozempic about $968 to $1,029 per month, per manufacturer pricing. Real out-of-pocket cost depends on coverage, savings cards, and the prescription's indication far more than on list price alone.

Does the Precision Peptide Genetic Test say which one will work?

No. It analyzes pathway-level variants in GIPR, GLP1R, FTO, and MC4R that shape baseline GLP-1 biology — upstream context that applies to either molecule. It is an educational tool describing your metabolic terrain, not a predictor of response to semaglutide, tirzepatide, or any specific drug.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.